CLAIMS

1. Use of a composition comprising mesenchymal lineage precursor or stem cells expressing one or more of the markers selected from the group consisting of α1, α2, α3, α4 and α5, αv, β1 and β3 in the manufacture of a medicament for treating cancer, in which the mesenchymal lineage precursor or stem cells are modified to introduce an oligonucleotide or a plasmid expressing the oligonucleotide.

2. Use of a mesenchymal lineage precursor or stem cell expressing one or more of the markers selected from the group consisting of α1, α2, α3, α4 and α5, αv, β1 and β3 in the manufacture of a medicament for delivering an oligonucleotide into a target cell, in which the mesenchymal lineage precursor or stem cell has been modified to introduce an oligonucleotide or a vector expressing the oligonucleotide.

3. Use according to Claim 1, in which the mesenchymal lineage precursor or stem cells are modified to introduce an inhibitory oligonucleotide or comprise a vector expressing the inhibitory oligonucleotide.

4. Use according to Claim 1, 2 or 3, in which modified mesenchymal lineage precursor or stem cells comprise sufficient levels of inhibitory oligonucleotide to effect transfer of between 0.5 to 5 nM of the inhibitory oligonucleotide to a target cell.

5. Use according to any preceding claim, in which the oligonucleotide is an siRNA.

6. Use according to Claim 5, in which the siRNA is a KIF11 siRNA or PLK1 siRNA.

7. Use according to Claim 5, in which the siRNA is a KIF11 siRNA which binds the KIF11 mRNA transcript as shown in SEQ ID NO: 1 between bp 800 and bp 3,600 from the 5' end.

8. Use according to any of Claims 1 to 4, in which the oligonucleotide is one or more of the following:

(i) about 12 – 24 nucleotides in length;

(ii) RNA;

(iii) an antisense molecule;

(iv) an shRNA or siRNA;

(v) comprises the nucleic acid sequence as shown in any one of SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8 or 9;

(vi) the oligonucleotide is 18-22 nucleotides in length;

(vii) miRNA; or

(viii) an miRNA selected from the group consisting of miR-155, miR-155-inh, miR-181-B1, miR-15a, miR-16-1, miR-21, miR-34a, miR-221, miR-29a, let-7b.

9. Use according to any of Claims 2 or 4 to 8, in which the mesenchymal lineage precursor or stem cells are modified to introduce an oligonucleotide or vector expressing the same that kills the target cell but does not substantially affect viability of the mesenchymal lineage precursor or stem cell.

10. Use according to any of Claims 2 or 4 to 8, in which the mesenchymal lineage precursor or stem cells are modified to introduce an inhibitory oligonucleotide or vector expressing the same that does not kill the mesenchymal lineage precursor or stem cells before they can deliver the inhibitory oligonucleotide to a target cell such as a cancer cell.

11. Use according to any preceding claim, in which the mesenchymal lineage precursor or stem cell is one or more of the following:

(i) STRO-1 positive;

(ii) substantially STRO-1^{bri};

(iii) CD46 positive;

(iv) derived from pluripotent cells;

(v) derived from induced pluripotent stem (iPS) cells;

(vi) a mesenchymal stem cell; or

(vii) culture expanded *in vitro* from a cryopreserved intermediate.

12. Use according to any of Claims 2 or 3 to 11, in which the target cell is:

(i) a cancer cell or white blood cell;

(ii) a lung cancer, pancreatic cancer, colorectal cancer, liver cancer, cervical cancer, prostate cancer, osteosarcoma or melanoma cell;

(iii) a syncytial cell; or

(iv) a cardiac myocyte, smooth muscle cell, epithelial cell, connective tissue cell or syncytial cancer cell.

13. Use according to any of Claims 1 to 8, 10 or 11, in which the cancer is selected from the group consisting of lung cancer, pancreatic cancer, colorectal cancer, liver cancer, cervical cancer, prostate cancer, osteosarcoma or melanoma.

14. Use according to Claim 13, in which the mesenchymal lineage precursor or stem cells express a connexin that is also expressed by a cancer cell comprising the subject's cancer.

15. Use according to Claim 14, in which the connexin is Cx40 or Cx43.

16. Use according to Claim 13 or 14, in which a cancer cell comprising the subject's cancer expresses Cx43.

17. Use according to any preceding claim, in which the mesenchymal lineage precursor or stem cell is modified to introduce the oligonucleotide using a viral vector, in which the viral vector is selected from the group consisting of Lentivirus, Baculovirus, Retrovirus, Adenovirus (AdV), Adeno-associated virus (AAV) or a recombinant form thereof.

18. Use according to Claim 17, in which the viral vector is a recombinant AAV.

19. Use according to any preceding claim, in which the modified mesenchymal lineage precursor or stem cell have been treated to effect modification of cell surface glycans on the mesenchymal lineage precursor or stem cell,in which the treatment involves exposure of the mesenchymal lineage precursor or stem cell to a glycosylstrasferase under conditions which result in modification of cell-surface glycans on the mesenchymal precursor lineage cell or stem cell, in which the mesenchymal lineage precursor or stem cell is exposed to an exogenous glycosyltranferase.

20. Use according to Claim 19, in which the glycosyltransferase is an alpha 1,3 fucosyltransferase such as an alpha 1,3 fucosyltransferase III, alpha 1,3 fucosyltransferase IV, an alpha 1,3 fucosyltransferase VI, an alpha 1,3 fucosyltransferase VII or an alpha 1,3 fucosyltransferase IX.